Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells

International Journal of Oncology

Volumn 46, Issue 3, 2015, Pages 963-972

  Wada, Naoko ^a   Kawano, Yawara ^b   Fujiwara, Shiho ^a   Kikukawa, Yoshitaka ^a   Okuno, Yutaka ^a   Tasaki, Masayoshi ^d   Ueda, Mitsuharu ^d   Ando, Yukio ^d   Yoshinaga, Kazuya ^e   Ri, Masaki ^c   Iida, Shinsuke ^c   Nakashima, Takayuki ^f   Shiotsu, Yukimasa ^f   Mitsuya, Hiroaki ^a   Hata, Hiroyuki ^a,d  

^a KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

^f KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Apoptosis; Heat shock protein; Multiple myeloma; Necroptosis; Proteasome

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CASPASE 3; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 72; LENALIDOMIDE; NECROSTATIN 1; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN INHIBITOR; SHIKONIN; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG; VER 155008; X BOX BINDING PROTEIN 1; BORONIC ACID DERIVATIVE; DNA BINDING PROTEIN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; NAPHTHOQUINONE; NECROSTATIN-1; PURINE NUCLEOSIDE; PYRAZINE DERIVATIVE; REGULATORY FACTOR X TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL DEATH; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY ASSAY; CELL VOLUME; CHROMATIN CONDENSATION; CYTOTOXICITY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC50; KMS11 CELL LINE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NECROPTOSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; NECROSIS; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; BORTEZOMIB; CELL DEATH; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENDOPLASMIC RETICULUM STRESS; HUMANS; IMIDAZOLES; INDOLES; MULTIPLE MYELOMA; NAPHTHOQUINONES; NECROSIS; PROTEASOME INHIBITORS; PURINE NUCLEOSIDES; PYRAZINES; TRANSCRIPTION FACTORS;

EID: 84921933135     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2804     Document Type: Article

References (39)

1. Palumbo A and Anderson K: Multiple myeloma. N Engl J Med 364: 1046-1060, 2011.
2. He S, Liao TT, Chen YT, Kuo HM and Lin YL: Glutathione-S-transferase enhances proliferation-migration and protects against shikonin-induced cell death in breast cancer cells. Kaohsiung J Med Sci 27: 477-484, 2011.
3. Duan D, Zhang B, Yao J, Liu Y and Fang J: Shikonin targets cytosolic thioredoxin reductase to induce ROS-mediated apoptosis in human promyelocytic leukemia HL-60 cells. Free Radic Biol Med 70: 182-193, 2014.
4. Yoon Y, Kim YO, Lim NY, Jeon WK and Sung HJ: Shikonin, an ingredient of Lithospermum erythrorhizon induced apoptosis in HL60 human premyelocytic leukemia cell line. Planta Med 65: 532-535, 1999.
5. Mao X, Yu CR, Li WH and Li WX: Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells. Cell Res 18: 879-888, 2008.
6. Jang SY, Jang EH, Jeong SY and Kim JH: Shikonin inhibits the growth of human prostate cancer cells via modulation of the androgen receptor. Int J Oncol 44: 1455-1460, 2014.
7. Hsu PC, Huang YT, Tsai ML, Wang YJ, Lin JK and Pan MH: Induction of apoptosis by shikonin through coordinative modulation of the Bcl-2 family, p27, and p53, release of cytochrome c, and sequential activation of caspases in human colorectal carcinoma cells. J Agric Food Chem 52: 6330-6337, 2004.
8. Chen CH, Lin ML, Ong PL and Yang JT: Novel multiple apoptotic mechanism of shikonin in human glioma cells. Ann Surg Oncol 19: 3097-3106, 2012.
9. Ahn J, Won M, Choi JH, et al: Reactive oxygen species-mediated activation of the Akt/ASK1/p38 signaling cascade and p21(Cip1) downregulation are required for shikonin-induced apoptosis. Apoptosis 18: 870-881, 2013.
10. Min R, Tong J, Wenjun Y, et al: Growth inhibition and induction of apoptosis in human oral squamous cell carcinoma Tca-8113 cell lines by Shikonin was partly through the inactivation of NF-kappaB pathway. Phytother Res 22: 407-415, 2008.
11. Yang H, Zhou P, Huang H, et al: Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int J Cancer 124: 2450-2459, 2009.
12. Zhang FL, Wang P, Liu YH, et al: Topoisomerase I inhibitors, shikonin and topotecan, inhibit growth and induce apoptosis of glioma cells and glioma stem cells. PLoS One 8: e81815, 2013.
13. Ahmed K, Furusawa Y, Tabuchi Y, et al: Chemical inducers of heat shock proteins derived from medicinal plants and cytoprotective genes response. Int J Hyperthermia 28: 1-8, 2012.
14. Eremenko EM, Antimonova OI, Shekalova OG, Polonik SG, Margulis BA and Guzhova IV: Novel compounds increasing chaperone Hsp70 expression and their biological activity. Tsitologiia 52: 235-241, 2010 (In Russian).
15. Munshi NC, Hideshima T, Carrasco D, et al: Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 103: 1799-1806, 2004.
16. Nimmanapalli R, Gerbino E, Dalton WS, Gandhi V and Alsina M: HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. Br J Haematol 142: 551-561, 2008.
17. Chatterjee M, Andrulis M, Stuhmer T, et al: The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica 98: 1132-1141, 2013.
18. Fu Z, Deng B, Liao Y, et al: The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis. BMC Cancer 13: 580, 2013.
19. Huang C, Luo Y, Zhao J, et al: Shikonin kills glioma cells through necroptosis mediated by RIP-1. PLoS One 8: e66326, 2013.
20. Degterev A, Huang Z, Boyce M, et al: Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 1: 112-119, 2005.
21. Hitomi J, Christofferson DE, Ng A, et al: Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 135: 1311-1323, 2008.
22. Degterev A, Hitomi J, Germscheid M, et al: Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 4: 313-321, 2008.
23. Cai Z, Jitkaew S, Zhao J, et al: Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat Cell Biol 16: 55-65, 2014.
24. Gunther C, Martini E, Wittkopf N, et al: Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature 477: 335-339, 2011.
25. Sawai H and Domae N: Discrimination between primary necrosis and apoptosis by necrostatin-1 in Annexin V-positive/propidium iodide-negative cells. Biochem Biophys Res Commun 411: 569-573, 2011.
26. Chromik J, Safferthal C, Serve H and Fulda S: Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis. Cancer Lett 344: 101-109, 2014.
27. Ohtsuki T, Yawata Y, Wada H, Sugihara T, Mori M and Namba M: Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32). Br J Haematol 73: 199-204, 1989.
28. Matsuoka Y, Moore GE, Yagi Y and Pressman D: Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med 125: 1246-1250, 1967.
29. Togawa A, Inoue N, Miyamoto K, Hyodo H and Namba M: Establishment and characterization of a human myeloma cell line (KMM-1). Int J Cancer 29: 495-500, 1982.
30. Ikeyama S, Nakagawa S, Arakawa M, Sugino H and Kakinuma A: Purification and characterization of IgE produced by human myeloma cell line, U266. Mol Immunol 23: 159-167, 1986.
31. Namba M, Ohtsuki T, Mori M, et al: Establishment of five human myeloma cell lines. In Vitro Cell Dev Biol 25: 723-729, 1989.
32. Ri M, Iida S, Nakashima T, et al: Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 24: 1506-1512, 2010.
33. Uneda S, Hata H, Matsuno F, et al: Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol 120: 53-55, 2003.
34. Nakamura M, Gotoh T, Okuno Y, et al: Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cells. Leuk Lymphoma 47: 531-539, 2006.
35. Tatetsu H, Ueno S, Hata H, et al: Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. Cancer Res 67: 5328-5336, 2007.
36. Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446, 2010.
37. Zhang L, Fok JJ, Mirabella F, et al: Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress. Cancer Lett 339: 49-59, 2013.
38. Garcia-Carbonero R, Carnero A and Paz-Ares L: Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol 14: e358-369, 2013.
39. Christofferson DE and Yuan J: Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol 22: 263-268, 2010.